Ocugen, Inc. (OCGN) Stock Analysis
A live, multi-source view of Ocugen, Inc. (OCGN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Sector: Healthcare · Industry: Biotechnology · United States · 116 employees · ocugen.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Ocugen, Inc. (OCGN) had a market capitalization of $461.2M (forward -5.1) and a beta of 2.21; the shares traded in a 52-week range of $1.01 – $2.73 (31.1% over the year).
- Market cap
- $461.2M
- Enterprise value
- $449.1M
- Forward P/E
- -5.1
- EPS (trailing)
- $-0.26
- EPS (forward)
- $-0.27
- Payout ratio
- 0.0%
- 52-week range
- $1.01 – $2.73
- 52-week change
- 31.1%
- Beta
- 2.21
- Average volume
- 6.1M
- Shares outstanding
- 339.1M
- Short % of float
- 30.17%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Ocugen, Inc. (OCGN) last closed at $1.03 (the last completed close before that scan).
Technicals at the scan: RSI 27 (oversold territory), price -22.9% versus its 20-day average, 20-day versus 50-day average spread -0.7%, MACD histogram -0.03.
Sentiment inputs: 60% of recent Finnhub-scored headlines read bullish; StockTwits 88% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 79/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for OCGN in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
OCGN has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-06-16, rank #1, +20.07% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls Ocugen, Inc. (OCGN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell OCGN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.